Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 501–600 of 1,010
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Proverbs-Singh, T. A., Feldman, J. L., Morris, M. J., Autio, K. A., & Traina, T. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0543 · Cited by 97
Massard, C., Chi, K. N., Castellano, D., Bono, J. S. D., Gravis, G., Dirix, L. Y., Machiels, J., Mita, A. C., Mellado, B., Turri, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.024 · Cited by 91
Self-citationCai, L., Tsai, Y., Wang, P., Wang, J., Li, D., Fan, H., Zhao, Y., Bareja, R., Lu, R., Wilson, E. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.029 · Cited by 96
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Wada, S., Jackson, C. M., Yoshimura, K., Yen, H., Getnet, D., Harris, T. J., Goldberg, M. V., Bruno, T. C., Grosso, J. F., Durham, N. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-89 · Cited by 99
“Recently, metastatic castrate-resistant prostate cancer (mCRPC) has been shown to remain sensitive to hormonal manipulation [4], and the androgen biosynthesis inhibitor abiraterone acetate is now FDA-approved in the post-docetaxel setting [5].”
BackgroundThe Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
Sprenger, C. C. T., & Plymate, S. R. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0177-y · Cited by 101
“1) [11–14].”
Mulders, P., Molina, A., Marberger, M., Saad, F., Higano, C. S., Chi, K. N., Li, J., Kheoh, T. S., Haqq, C. M., & Fizazi, K. S. (2013) · European Urology · doi:10.1016/j.eururo.2013.09.005 · Cited by 90
“govidentifierNCT00638690) was a phase 3 multinational, randomised double-blind PLcontrolled study described previously [10,11].”
BackgroundResultInfluentialSelf-citationAndrogen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Imamura, Y., & Sadar, M. D. (2016) · International Journal of Urology · doi:10.1111/iju.13137 · Cited by 86
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance
Yeh, Y. A., Guo, Q., Connelly, Z. M., Cheng, S., Yang, S., Prieto‐Domínguez, N., & Yu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_16 · Cited by 99
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 98
Harland, S. J., Staffurth, J. N., Molina, A., Hao, Y., Gagnon, D. D., Sternberg, C. N., Cella, D. F., Fizazi, K. S., Logothetis, C. J., Kheoh, T. S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.144 · Cited by 87
“These benefits were in addition to a previously reported advantage in OS and were achieved with a good tolerability profile [11,12].”
BackgroundSelf-citationLi, A., Turró, C., & Kodanko, J. J. (2018) · Chemical Communications · doi:10.1039/c7cc09000e · Cited by 99
Opportunities and challenges in combination gene cancer therapy
Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85
Deek, M. P., Taparra, K., Phillips, R., Velho, P. I., Gao, R. W., Deville, C., Song, D. Y., Greco, S., Carducci, M., Eisenberger, M., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2020.05.004 · Cited by 96
Sex hormones and prostate cancer
Auchus, R. J., & Sharifi, N. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051418-060357 · Cited by 85
AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
Tortorella, E., Giantulli, S., Sciarra, A., & Silvestri, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032046 · Cited by 109
“Because of interaction with numerous targets, steroid supplementation is necessary to overcome cortisol insufficiency and limit some adverse effects (AEs) [20].”
BackgroundRuthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage
Zamora, A., Denning, C. A., Heidary, D. K., Wachter, E., Nease, L. A., Ruiz, J., & Glazer, E. C. (2017) · Dalton Transactions · doi:10.1039/c6dt04405k · Cited by 86
Expanding Treatment Options for Metastatic Prostate Cancer
Antonarakis, E. S., & Eisenberger, M. A. (2011) · New England Journal of Medicine · doi:10.1056/nejme1102758 · Cited by 85
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
Madan, R. A., Bilusic, M., Heery, C., Schlom, J., & Gulley, J. L. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.010 · Cited by 84
Cheng, H. H., Gulati, R., Azad, A., Nadal, R., Twardowski, P., Vaishampayan, U. N., Agarwal, N., Heath, E. I., Pal, S. K., Rehman, H.-T., et al. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.53 · Cited by 88
Self-citationRathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D. W., Lakhani, N. J., Hawley, J. E., Srinivas, S., Aparicio, A. M., Narayan, V., Runcie, K. D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.005 · Cited by 97
Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Bumbaca, B., & Li, W. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.007 · Cited by 90
Sharp, A., Welti, J. C., Lambros, M. B. K., Dolling, D. I., Rodrigues, D. N., Pope, L., Aversa, C., Figueiredo, I., Fraser, J. A., Ahmad, Z., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.04.006 · Cited by 86
Self-citationCrona, D. J., Milowsky, M., & Whang, Y. E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.256 · Cited by 87
“, more advanced disease, greater tumor burden, and more symptoms) were observed more frequently in enzalutamide-refractory patients who received abiraterone, when compared to the original phase III abiraterone trial, and could conceivably account for the modest response and a shorter PFS that was observed.(10,38) Ther…”
BackgroundMethodResultMoreira, R. B., Debiasi, M., Francini, E., Nuzzo, P. V., de Velasco, G., Maluf, F. C., Fay, A. P., Joaquim Bellmunt, B., Choueiri, T. K., & Schutz, F. A. B. (2017) · Oncotarget · doi:10.18632/oncotarget.20028 · Cited by 89
“As both abiraterone and enzalutamide demonstrated similar efficacy prior to and after chemotherapy in mCRPC patients [3] [4], the treatment decision-making should be aided by a careful analysis of patient competing risks of death, chiefly a history of cardiovascular disease or cardiac comorbidities, and patient baseli…”
BackgroundLi, Y., Yang, R., Henzler, C. M., Ho, Y., Passow, C. N., Auch, B., Carreira, S., Rodrigues, D. N., Bertan, C. M., Hwang, T. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3023 · Cited by 92
Zhao, J., Ning, S., Lou, W., Yang, J. C., Armstrong, C. M., Lombard, A. P., D'Abronzo, L. S., Evans, C. P., Gao, A. C., & Liu, C. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0015 · Cited by 86
“The antiandrogen therapies, including abiraterone, enzalutamide, apalutamide, and darolutamide, significantly improved patient overall survival (OS) rate and are approved by the FDA (6–9).”
BackgroundInfluentialLee, H.-C., Ou, C.-H., Huang, Y., Hou, P., Creighton, C. J., Lin, Y.-S., Hu, C., & Lin, S. (2021) · Oncogene · doi:10.1038/s41388-021-01718-4 · Cited by 93
Vaccines as treatments for prostate cancer
Rastogi, I., Muralidhar, A., & McNeel, D. G. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00739-w · Cited by 91
Caffo, O., Giorgi, U. D., Fratino, L., Alesini, D., Zagonel, V., Facchini, G., Gasparro, D., Ortega, C., Tucci, M., Verderame, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.10.014 · Cited by 86
D'Amico, A. V., Chen, M., de Castro, M., Loffredo, M. J., Lamb, D. S., Steigler, A., Kantoff, P. W., & Denham, J. W. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70295-9 · Cited by 88
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)
ICECaP Working Group (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv261 · Cited by 89
Woo, H., Park, J., Ku, J. Y., Lee, C. H., Sunkara, V., Ha, H. K., & Cho, Y. (2018) · Lab on a Chip · doi:10.1039/c8lc01185k · Cited by 87
Zhang, T., Karsh, L. I., Nissenblatt, M. J., & Canfield, S. E. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.09.015 · Cited by 95
“The ideal of personalized medicine is to individualize care by identifying and targeting the unique molecular characteristics of a given patient or tumor; however, prostate cancer has historically been bereft of such targetable markers of response and resistance.(6,21)”
BackgroundChoi, E., Buie, J. D., Camacho, J., Sharma, P., & de Riese, W. T. W. (2022) · Research and Reports in Urology · doi:10.2147/rru.s303215 · Cited by 125
Mathematical modeling of prostate cancer progression in response to androgen ablation therapy
Jain, H. V., Clinton, S. K., Bhinder, A., & Friedman, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115750108 · Cited by 91
“These agents act by different mechanisms, including: (i) inhibition of testicular testosterone production by down-regulation of gonadotropin-releasing hormone production by the pituitary, (ii) blocking the ability of testosterone to bind the androgen receptor, (iii) inhibition of the 5α-reductase enzyme responsible fo…”
BackgroundMethodCYP17A1 inhibitors in castration-resistant prostate cancer
Gomez, L., Kovac, J. R., & Lamb, D. J. (2015) · Steroids · doi:10.1016/j.steroids.2014.12.021 · Cited by 91
“Enrolled patients (n=1,195) were randomized to receive AA plus prednisone (n=797) or placebo plus prednisone (n=398) [68].”
BackgroundInfluentialSipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
Graff, J. N., & Chamberlain, E. D. (2014) · Core evidence · doi:10.2147/ce.s54712 · Cited by 105
Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer
Wilczak, W., Wittmer, C., Clauditz, T. S., Minner, S. J. P., Steurer, S. A., Büscheck, F., Krech, T., Lennartz, M., Harms, L., Leleu, D., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.05.034 · Cited by 87
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
Montgomery, B., Eisenberger, M. A., Rettig, M. B., Chu, F. M., Пили, Р., Stephenson, J. J., Vogelzang, N. J., Koletsky, A. J., Nordquist, L. T., Edenfield, W. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1432 · Cited by 84
Calopedos, R. J. S., Chalasani, V., Asher, R., Emmett, L., & Woo, H. H. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2017.23 · Cited by 89
Exercise medicine for advanced prostate cancer
Hart, N. H., Galvao, D. A., & Newton, R. U. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000276 · Cited by 91
“as second-line hormonal therapies to countenance extragonadal sources of androgen, including derivations from blood and bone marrow, successfully extending overall survival by 4–5 months [78,79] in castrate-resistant patients.”
BackgroundEnzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Tucci, M., Zichi, C., Buttigliero, C., Vignani, F., Scagliotti, G. V., & Maïo, M. D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153764 · Cited by 93
Ng, K., Smith, S., & Shamash, J. (2020) · Oncology and Therapy · doi:10.1007/s40487-020-00119-z · Cited by 89
Mori, K., Mostafaei, H., Pradère, B., Motlagh, R. S., Quhal, F., Laukhtina, E., Schuettfort, V. M., Abufaraj, M. M., Karakiewicz, P. I., Kimura, T., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01777-9 · Cited by 85
McKay, R. R., Xie, W., Ye, H., Fennessy, F. M., Zhang, Z., Lis, R. T., Calagua, C., Rathkopf, D. E., Laudone, V. P., Bubley, G. J., et al. (2021) · The Journal of Urology · doi:10.1097/ju.0000000000001702 · Cited by 84
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
Hatano, K., & Nonomura, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.220200 · Cited by 87
Padhi, D., Higano, C. S., Shore, N. D., Sieber, P., Rasmussen, E., & Smith, M. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1271 · Cited by 81
“Diarrhea 2 (9) 0 (0) 0 (0) 4 (21) 4 (13) 6 (11) Contusion 0 (0) 0 (0) 0 (0) 3 (16) 3 (10) 3 (6) E1970 Padhi et al Myostatin Inhibition and Changes in Lean Body Mass J Clin Endocrinol Metab, October 2014, 99(10):E1967–E1975”
Corn, P. G. (2012) · Cancer Management and Research · doi:10.2147/cmar.s32839 · Cited by 96
Walker, L. M., Tran, S., & Robinson, J. W. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.05.004 · Cited by 87
Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
Šeruga, B., & Tannock, I. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3996 · Cited by 91
Drug-induced hepatotoxicity in cancer patients - implication for treatment
Vincenzi, B., Armento, G., Ceruso, M. S., Catania, G., Leakos, M., Santini, D., Minotti, G., & Tonini, G. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1194824 · Cited by 89
“In a randomized Phase III study [195], in which 1195”
BackgroundSpliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer
Jiménez‐Vacas, J. M., Herrero‐Aguayo, V., Gómez‐Gómez, E., León‐González, A. J., Sáez-Martínez, P., Alors‐Pérez, E., Fuentes-Fayos, A. C., Martínez-López, A., Sánchez‐Sánchez, R., González-Serrano, T., et al. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.001 · Cited by 86
Clinical significance of 11-oxygenated androgens
Turcu, A. F., & Auchus, R. J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000334 · Cited by 80
Loddick, S. A., Ross, S. J., Thomason, A. G., Robinson, D. M., Walker, G. E., Dunkley, T. P. J., Brave, S. R., Broadbent, N., Stratton, N. C., Trueman, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1174 · Cited by 79
“Furthermore, this class of compound showed antitumor activity in the HID28 mouse model of CRPC in vivo.”
BackgroundInfluentialSelf-citationYin, X., Xiao, Y., Li, F., Qi, S., Yin, Z., & Gao, J. (2016) · Medicine · doi:10.1097/md.0000000000002544 · Cited by 99
Ponnusamy, S., He, Y., Hwang, D., Thiyagarajan, T., Houtman, R., Bocharova, V., Sumpter, B. G., Fernandez, E. J., Johnson, D. L., Du, Z., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1458 · Cited by 83
“About 30%–40% of CRPCs fail to respond to enzalutamide or abiraterone (2, 3, 6, 7), while the remaining CRPCs eventually develop resistance after a brief period of response (8).”
BackgroundParikh, M., Liu, C., Wu, C., Evans, C. P., Dall’Era, M., Robles, D., Lara, P. N., Agarwal, N., Gao, A. C., & Pan, C.-X. (2021) · Scientific Reports · doi:10.1038/s41598-021-85969-x · Cited by 86
Varkaris, A. S., Corn, P. G., Gaur, S., Dayyani, F., Logothetis, C. J., & Gallick, G. E. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.631523 · Cited by 95
“While both chemotherapies (such as docetaxel and cabazitaxel) and androgen-ablative therapies (such as abiraterone acetate) have improved the survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) [4-6], nearly every patient with bone metastasis eventually succumbs to the disease.”
BackgroundSelf-citationSwitching and withdrawing hormonal agents for castration-resistant prostate cancer
Lorente, D., Mateo, J., Zafeiriou, Z., Smith, A. D., Sandhu, S. K., Ferraldeschi, R., & Bono, J. S. D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2014.345 · Cited by 98
Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer
Agarwal, N., Sonpavde, G., & Sternberg, C. N. (2011) · European Urology · doi:10.1016/j.eururo.2011.12.028 · Cited by 82
“The realization of the importance of androgen-mediated signaling led to the eventual approval of abiraterone acetate, the CYP17 and potent androgen synthesis inhibitor, in the second-line postdocetaxel setting [3].”
BackgroundInfluentialSelf-citationFaugeroux, V., Pailler, E., Oulhen, M., Déas, O., Brullé, L., Hervieu, C., Marty, V., Alexandrova, K., Andree, K., Stoecklein, N. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15426-2 · Cited by 89
Self-citationHeidenreich, A., Rawal, S. K., Szkarlat, K., Bogdanova, N. V., Dirix, L. Y., Stenzl, A., Welslau, M., Wang, G., Dawkins, F. W., de Boer, C. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds505 · Cited by 85
Nowak, D. G., Cho, H., Herzka, T., Watrud, K., DeMarco, D. V., Wang, V. M. Y., Senturk, S., Fellmann, C., Ding, D., Beinortas, T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1113 · Cited by 79
Ramos‐Montoya, A., Lamb, A. D. G., Russell, R., Carroll, T. D., Jurmeister, S., Galeano-Dalmau, N., Massie, C. E., Boren, J., Bon, H., Theodorou, V., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303581 · Cited by 91
“…therapeutics with wide-ranging modes of action have reinforced the concept that castrate-resistant prostate cancer is a heterogeneous disease with multiple mechanisms of resistance (de Bono et al , 2010, 2011; Kantoff et al , 2010; Nilsson et al , 2011; Scher et al , 2012; Ryan et al , 2013).”
Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy
Narayanan, S., Srinivas, S., & Feldman, D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.254 · Cited by 90
Bono, J. S. D., Smith, M. R., Saad, F., Rathkopf, D. E., Mulders, P., Small, E. J., Shore, N. D., Fizazi, K. S., Porre, P. D., Kheoh, T. S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.033 · Cited by 88
“0001) compared to placebo and prednisone or prednisolone 5 mg twice daily (hereafter referred to as P) [10,12].”
BackgroundSelf-citationMcClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0123 · Cited by 78
“Studies in model systems, and in patients, have confirmed that the androgen receptor (AR) signaling axis remains a key therapeutic target in CRPC, and novel approaches to androgen biosynthesis inhibition and androgen receptor blockade have resulted in improved patient outcomes (1,2).”
BackgroundMeisel, A., von Felten, S., Vogt, D., Liewen, H., de Wit, R., Bono, J. S. D., Sartor, O. A., & Stenner, F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.009 · Cited by 84
SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression
Kawamura, N., Nimura, K., Saga, K., Ishibashi, A., Kitamura, K., Nagano, H., Yoshikawa, Y., Ishida, K., Nonomura, N., Arisawa, M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3965 · Cited by 85
Liu, B., Li, L., Yang, G., Geng, C., Luo, Y., Wu, W., Manyam, G. C., Korentzelos, D. K., Park, S., Tang, Z., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0317 · Cited by 82
“8months for patients withmetastatic CRPC, respectively (1, 2).”
BackgroundIshizaki, F., Nishiyama, T., Kawasaki, T., Miyashiro, Y., Hara, N., Takizawa, I., Naito, M., & Takahashi, K. (2013) · Scientific Reports · doi:10.1038/srep01528 · Cited by 90
Cancer and Age: General Considerations
Hoffe, S. E., & Balducci, L. (2012) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.09.001 · Cited by 87
Shiota, M., & Eto, M. (2016) · International Journal of Urology · doi:10.1111/iju.13091 · Cited by 80
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 86
Heinrich, D. A., Bruland, Ø. S., Guise, T. A., Suzuki, H., & Sartor, O. A. (2018) · Future Oncology · doi:10.2217/fon-2018-0087 · Cited by 86
Heidenreich, A., Scholz, H.-J., Rogenhofer, S., Arsov, C., Retz, M. M., Müller, S. C., Albers, P., Gschwend, J. E., Wirth, M. P., Steiner, U., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.08.058 · Cited by 81
“8mo, respectively, when compared with mitoxantrone and placebo, respectively [4,5].”
BackgroundRyan, C. J., Rosenthal, M. A., Ng, S. S. W., Alumkal, J. J., Picus, J., Gravis, G., Fizazi, K. S., Forget, F., Machiels, J.-P., Srinivas, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2605 · Cited by 81
“Docetaxel is considered standard front-line chemotherapy (4, 5).”
BackgroundSelf-citationEnzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. T., & Preković, S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0289 · Cited by 85
Kalogirou, C., Linxweiler, J., Schmucker, P., Snaebjornsson, M. T., Schmitz, W., Wach, S., Krebs, M., Hartmann, E., Puhr, M., Müller, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25325-9 · Cited by 86
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015
Lowrance, W. T., Roth, B. J., Kirkby, E., Murad, M. H., & Cookson, M. S. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.10.086 · Cited by 79
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach
Sridaran, D., Bradshaw, E., DeSelm, C. J., Pachynski, R. K., Mahajan, K. N., & Mahajan, N. P. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101199 · Cited by 94
Loriot, Y., Eymard, J., Patrikidou, A., Ileana, E. E., Massard, C., Albiges, L. K., Palma, M. D., Escudier, B. J., & Fizazi, K. S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.128 · Cited by 84
“In the COU-301 trial, the OS benefit was also observed in patients with visceral disease, and in those with various types of disease progression, consistent with our data [4,5,23].”
BackgroundResultSelf-citationTilki, D., Schaeffer, E. M., & Evans, C. P. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.11.013 · Cited by 85
“A survival benefit of abiraterone/prednisone over placebo/prednisone has been demonstrated in patients who had progressed on docetaxel therapy and in the prechemotherapy setting [39,40].”
BackgroundTranscriptional Regulation in Prostate Cancer
Labbé, D. P., & Brown, M. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030437 · Cited by 82
Liu, C., Yang, J. C., Armstrong, C. M., Lou, W., Liu, L., Qiu, X., Zou, B., Lombard, A. P., D'Abronzo, L. S., Evans, C. P., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1322 · Cited by 77
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
Cattrini, C., Castro, E., Mejorada, R. L., Zanardi, E., RUBAGOTTI, A., Boccardo, F., & Olmos, D. (2019) · Cancers · doi:10.3390/cancers11091355 · Cited by 90
“Abiraterone acetate is an inhibitor of extragonadal androgen biosynthesis that was initially approved for the treatment of mCRPC [43,44].”
BackgroundTiwari, R., Manzar, N., Bhatia, V., Yadav, A., Nengroo, M. A., Datta, D. B., Carskadon, S. L., Gupta, N., Sigouros, M., Khani, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14184-0 · Cited by 81
Mosquera, M. J., Kim, S., Bareja, R., Fang, Z., Cai, S., Pan, H., Asad, M. I., Martín, M. L., Sigouros, M., Rowdo, F. P. M., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100096 · Cited by 87
Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2978 · Cited by 76
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Kulasegaran, T., & Oliveira, N. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01215-2 · Cited by 101
“This effect can be mitigated by the concurrent use of low-dose prednisolone [24, 25].”
BackgroundMinireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1007 · Cited by 76
“The extension of survival conferred by agents that deplete intratumoral androgens serves as the most definitive evidence that androgen synthesis plays a central role in the progression of CRPC (20, 21).”
Antonarakis, E. S., Chandhasin, C., Osbourne, E., Luo, J., Sadar, M. D., & Perabo, F. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0161 · Cited by 83
Sartor, O. A., Vogelzang, N. J., Sweeney, C. J., Fernandez, D. C., Almeida, F., Iagaru, A. H., Brown, A. S., Smith, M. R., Agrawal, M., Dicker, A. P., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0413 · Cited by 78
“These options are docetaxel [1], sipuleucel-T [2], cabazitaxel [3], abiraterone acetate (abiraterone) [4], enzalutamide [5], and radium-223 dichloride (radium223), a targeted alpha therapy [6]; each improved overall survival (OS) versus placebo or standard of care in randomized controlled trials.”
BackgroundMetastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or…
Barata, P. C., & Sartor, O. A. (2019) · Cancer · doi:10.1002/cncr.32039 · Cited by 78
Han, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 86
Self-citationUpregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth
Scott, E., Hodgson, K., de la Calle, B., Turner, H., Cheung, K., Bermudez, A., Garcia-Marques, F. J., Pye, H., Yo, E. C., Islam, M. K., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02604-x · Cited by 80
“receptor signalling axis, such as abiraterone [3] and enzalutamide [4] are available for CRPC, however nearly all affected men will also develop resistance to these agents [5].”
Ardiani, A., Gameiro, S. R., Kwilas, A. R., Donahue, R. N., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.2429 · Cited by 78
Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
Chang, K.-H., Ercole, C. E., & Sharifi, N. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.268 · Cited by 85
“The clinical benefit of the CYP17A1 inhibitor abiraterone acetate demonstrates the concept that androgen metabolism is a central driver of CRPC progression (de Bono et al, 2011; Ryan et al, 2013).”
BackgroundHSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Hearn, J. W. D., Sweeney, C. J., Almassi, N., Reichard, C. A., Reddy, C. A., Li, H., Hobbs, B. P., Jarrard, D. F., Chen, Y., Dreicer, R., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6496 · Cited by 82
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.